Navigation Links
Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results
Date:7/30/2009

CHADDS FORD, Pa., July 30 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today reported financial results for the second quarter of 2009, including a full quarter of results of Indevus Pharmaceuticals, Inc., which Endo acquired during the first quarter.

Total revenues during the second quarter of 2009 increased 22 percent to $373.1 million compared with $306.2 million in the second quarter of 2008. Net income for the three months ended June 30, 2009, was $30.0 million, compared with $57.1 million in the comparable 2008 period. As detailed in the supplemental financial information below, adjusted net income for the three months ended June 30, 2009, was $85.9 million, compared with $72.7 million in the same period in 2008. Diluted earnings per share for the three months ended June 30, 2009, were $0.26 compared with $0.46 in the second quarter of 2008. Adjusted diluted earnings per share for the three months ended June 30, 2009, were $0.73, compared with $0.59 in the same period in 2008.

Total revenues for the six months ended June 30, 2009, were $708.4 million, compared with $596.4 million in the comparable 2008 period. Diluted earnings per share for the six months ended June 30, 2009, were $0.59, compared with $0.90 in the comparable 2008 period. Adjusted diluted earnings per share for the six months ended June 30, 2009, were $1.41, compared with $1.09 in the same period in 2008.

    ($in thousands, except
     per share amounts)

                             Second Quarter             Year-to-Date
                        2009      2008   Change     2009      2008      Change
    Total Revenues    $373,108  $306,161    22%   $708,408   $596,432     19%
    Reported Net
     Income             30,029    57,128   (47%)    69,066
'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014 Naurex Inc., a biopharmaceutical company ... diseases of the central nervous system, today announced that ... officer, will present at the 33 rd annual ... place at 3:00 p.m. PST on Tuesday, January 13, ... San Francisco, Calif. About ...
(Date:12/19/2014)... Mass. , Dec. 19, 2014 Decision ... market will grow at a 12 percent compound annual ... result of the aging population and the increasing adoption ... Latin America will also spur demand for ... of dental implant and periodontal treatments. Other ...
(Date:12/19/2014)... 18, 2014 Today, TiFiber, ... pilot production facility and future company headquarters in ... innovative new materials that safely and effectively control ... because of its historic, strong support for manufacturing, ... attract leading edge, technology-based companies such as TiFiber. ...
(Date:12/19/2014)... MA (PRWEB) December 18, 2014 Reports ... in the United States suffer from one or more ... asthma, or cancer. Medication can address some of these ... daily activities that many sufferers face. While implanted nerve ... and stimulate the whole nerve, which can induce side ...
Breaking Biology Technology:Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2
... could improve the life of the lithium batteries ... players, and mobile phones. Research to be published ... Nanomanufacturing - demonstrates that carbon nanotubes can prevent ... time. , Researchers at the Shenyang National Laboratory ...
... 10 Hologic, Inc.,(Nasdaq: HOLX ) today ... presenting at the Sun Trust Robinson Humphrey,s 37th ... Ritz-Carlton Hotel in,Buckhead, GA., Interested parties are ... of,Hologic,s investor presentation on Wednesday, April 16, 2008, ...
... are 14 prescription drugs that,exceeded $20 billion in sales in ... in four years. Prescription to OTC switches,were frequent in 2006 ... of the Rx to OTC Switch: Market Analysis and Product ... Rx to OTC are forecast to reach $5 billion in ...
Cached Biology Technology:Sweet nanotech batteries 2Hologic to Present at the Sun Trust Robinson Humphrey's 37th Annual Institutional Conference 2Use of Rx to OTC Switch as Product Management Tactic Enjoys Comeback 2
(Date:12/3/2014)... 2, 2014 As part of our commitment ... is pleased to announce the release of a new ... collect the workforce data that they need. ... left by existing readers. Many such devices have serious ... modern technology. Older models force users to navigate numerous ...
(Date:11/21/2014)... Nov. 20, 2014 C-Labs LLC, a leading ... of Things (IoT), today announced the appointment of ... officer. Previously a strategic advisor to the firm, Mr. ... Mr. Traynor is based out of the C-Labs office ... to Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... -- The Parenteral Drug Association (PDA) today confirmed that seven ... at least seven more will participate in the upcoming 2014 ... in Washington D.C. , Dec. 2-4. ... from the regulatory agencies in the United States ... effort to help advance the use of metrics in the ...
Breaking Biology News(10 mins):Inception Technologies to Release New Biometric Reader 2C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... ahead of a deadly disease that has wiped out more ... continue to discover new frog species in Panama: Pristimantis ... adnus from Darien Province near the Colombian border. , ... world. Then they identified the cause: a fungal disease called ...
... Irvine scientists have created an eight-layer, early-stage retina from ... to be made from stem cells. It also ... retinas to treat eye disorders such as retinitis pigmentosa ... a complex structure consisting of many cell types," said ...
... Medicine have identified in mice a previously unknown protective ... clots and other blockages from the brain. The findings ... age-related cognitive decline, Alzheimer,s disease and recovery from stroke. ... May 27 issue of Nature by Jaime ...
Cached Biology News:2 new frog species discovered in Panama's fungal war zone 2UCI researchers create retina from human embryonic stem cells 2Researchers discover new mechanism for clearing blockages from smallest blood vessels 2
... and ES1301 mutS are mismatch repair minus ... strains prevents repair of the newly synthesized ... efficiencies and making them helpful in such ... II Mutagenesis Systems. Both ES1301 and BMH ...
Request Info...
... ExcelGel DNA Analysis Kit, 1. ... polymorphisms and high resolution DNA typing. ... set-up and clean-up. *Precast, plastic-backed gels ... handling convenience and detection sensitivity. ...
For the quantitative determination of canine Interferon gamma,(IFN-γ) concentrations in cell culture supernates, serum and,plasma....
Biology Products: